Clinical trials investigating IL-1-targeting agents—such as anakinra (IL-1 receptor antagonist) and canakinumab (anti-IL-1β monoclonal antibody)—have not shown superiority over existing RA treatments like TNF-α inhibitors or IL-6 blockade (Singh et al., 2016). This evidence concerns the gene TNF and rheumatoid arthritis.